Saturday 17 October 2026
Export NTRB’s income statement to Excel — free account
Nutriband Inc.
NTRB Healthcare Biotechnology
Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.
6.22
0.05
−0.80%
Follow NTRB
Nutriband Inc. (NTRB) P/E ratio
Nutriband Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Apr 2026 | 0.0× | — |
| Jan 2026 | 0.0× | — |
| Oct 2025 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| NTRB Nutriband Inc. | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| PMN Promis Neurosciences compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)